Randomized, open-label, multicenter trial in treatment-naïve CLL patients

* Duration of treatment depended on response. Patients with complete response (CR), nodular partial response (nPR), or partial response (PR) after 3 cycles could receive 2 consolidation cycles, but no more than 6 cycles. Patients with stable disease had the option to receive up to 6 cycles. Patients with progressive disease discontinued treatment.¹

^†ORR includes patients with a best response of CR, nPR, and PR (ORR = CR + nPR + PR)

Efficacy was defined according to the National Cancer Institute Working Group (NCI-WG) guidelines.¹

Baseline characteristics were balanced in both treatment groups

Back to top

Reference:

1. Data on file. Cephalon, Inc.